Logo image of ASPI

ASP ISOTOPES INC (ASPI) Stock Fundamental Analysis

NASDAQ:ASPI - Nasdaq - US00218A1051 - Common Stock - Currency: USD

8.03  -0.33 (-3.95%)

Fundamental Rating

3

Taking everything into account, ASPI scores 3 out of 10 in our fundamental rating. ASPI was compared to 85 industry peers in the Chemicals industry. The financial health of ASPI is average, but there are quite some concerns on its profitability. ASPI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ASPI had negative earnings in the past year.
In the past year ASPI has reported a negative cash flow from operations.
ASPI Yearly Net Income VS EBIT VS OCF VS FCFASPI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

ASPI's Return On Assets of -40.29% is on the low side compared to the rest of the industry. ASPI is outperformed by 91.76% of its industry peers.
With a Return On Equity value of -86.12%, ASPI is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -40.29%
ROE -86.12%
ROIC N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASPI Yearly ROA, ROE, ROICASPI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Gross Margin of ASPI (37.40%) is better than 78.82% of its industry peers.
ASPI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASPI Yearly Profit, Operating, Gross MarginsASPI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

ASPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ASPI has been increased compared to 1 year ago.
ASPI has a worse debt/assets ratio than last year.
ASPI Yearly Shares OutstandingASPI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M
ASPI Yearly Total Debt VS Total AssetsASPI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 6.47 indicates that ASPI is not in any danger for bankruptcy at the moment.
The Altman-Z score of ASPI (6.47) is better than 97.65% of its industry peers.
A Debt/Equity ratio of 0.87 indicates that ASPI is somewhat dependend on debt financing.
ASPI has a worse Debt to Equity ratio (0.87) than 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z 6.47
ROIC/WACCN/A
WACC9.01%
ASPI Yearly LT Debt VS Equity VS FCFASPI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

ASPI has a Current Ratio of 7.21. This indicates that ASPI is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.21, ASPI belongs to the best of the industry, outperforming 97.65% of the companies in the same industry.
ASPI has a Quick Ratio of 7.17. This indicates that ASPI is financially healthy and has no problem in meeting its short term obligations.
ASPI has a Quick ratio of 7.17. This is amongst the best in the industry. ASPI outperforms 97.65% of its industry peers.
Industry RankSector Rank
Current Ratio 7.21
Quick Ratio 7.17
ASPI Yearly Current Assets VS Current LiabilitesASPI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

ASPI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.05%.
The Revenue has grown by 245.96% in the past year. This is a very strong growth!
EPS 1Y (TTM)-15.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22%
Revenue 1Y (TTM)245.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.08%

3.2 Future

Based on estimates for the next years, ASPI will show a very strong growth in Earnings Per Share. The EPS will grow by 46.60% on average per year.
The Revenue is expected to grow by 179.10% on average over the next years. This is a very strong growth
EPS Next Y71.93%
EPS Next 2Y44.49%
EPS Next 3Y32.97%
EPS Next 5Y46.6%
Revenue Next Year507.1%
Revenue Next 2Y313.14%
Revenue Next 3Y198.08%
Revenue Next 5Y179.1%

3.3 Evolution

ASPI Yearly Revenue VS EstimatesASPI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ASPI Yearly EPS VS EstimatesASPI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ASPI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ASPI is valuated quite expensively with a Price/Forward Earnings ratio of 157.45.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ASPI indicates a slightly more expensive valuation: ASPI is more expensive than 72.94% of the companies listed in the same industry.
ASPI is valuated expensively when we compare the Price/Forward Earnings ratio to 22.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 157.45
ASPI Price Earnings VS Forward Price EarningsASPI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASPI Per share dataASPI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ASPI does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as ASPI's earnings are expected to grow with 32.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.49%
EPS Next 3Y32.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASPI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASP ISOTOPES INC

NASDAQ:ASPI (6/13/2025, 2:38:41 PM)

8.03

-0.33 (-3.95%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)05-20 2025-05-20/amc
Earnings (Next)08-18 2025-08-18
Inst Owners44.73%
Inst Owner Change-1.09%
Ins Owners18.58%
Ins Owner Change9.58%
Market Cap602.73M
Analysts82.5
Price Target7.91 (-1.49%)
Short Float %30.26%
Short Ratio5.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.63%
Min EPS beat(2)-41.61%
Max EPS beat(2)-17.65%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.69%
Min Revenue beat(2)-16.92%
Max Revenue beat(2)-2.45%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.23%
PT rev (3m)19.23%
EPS NQ rev (1m)-120%
EPS NQ rev (3m)-175%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.67%
Revenue NQ rev (1m)-76.47%
Revenue NQ rev (3m)-78.38%
Revenue NY rev (1m)-22.46%
Revenue NY rev (3m)-24.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 157.45
P/S 136.81
P/FCF N/A
P/OCF N/A
P/B 14.18
P/tB 15.36
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)0.05
Fwd EY0.64%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS0.06
BVpS0.57
TBVpS0.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.29%
ROE -86.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.4%
FCFM N/A
ROA(3y)-45.32%
ROA(5y)N/A
ROE(3y)-74.55%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2414.15%
Cap/Sales 283.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.21
Quick Ratio 7.17
Altman-Z 6.47
F-Score6
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22%
EPS Next Y71.93%
EPS Next 2Y44.49%
EPS Next 3Y32.97%
EPS Next 5Y46.6%
Revenue 1Y (TTM)245.96%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%31.08%
Revenue Next Year507.1%
Revenue Next 2Y313.14%
Revenue Next 3Y198.08%
Revenue Next 5Y179.1%
EBIT growth 1Y-57.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-266.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-313.08%
OCF growth 3YN/A
OCF growth 5YN/A